- Home
- BLIN vs APM Comparison
BLIN vs APM Comparison
Compare BLIN & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- APM
- Stock Information
- Founded
- BLIN 2000
- APM 2010
- Country
- BLIN United States
- APM United Kingdom
- Employees
- BLIN N/A
- APM N/A
- Industry
- BLIN EDP Services
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- APM Health Care
- Exchange
- BLIN Nasdaq
- APM Nasdaq
- Market Cap
- BLIN 16.5M
- APM 18.9M
- IPO Year
- BLIN 2007
- APM 2018
- Fundamental
- Price
- BLIN N/A
- APM $1.59
- Analyst Decision
- BLIN Strong Buy
- APM
- Analyst Count
- BLIN 1
- APM 0
- Target Price
- BLIN $4.62
- APM N/A
- AVG Volume (30 Days)
- BLIN 209.5K
- APM 394.8K
- Earning Date
- BLIN 08-14-2025
- APM 04-30-2025
- Dividend Yield
- BLIN N/A
- APM N/A
- EPS Growth
- BLIN N/A
- APM N/A
- EPS
- BLIN N/A
- APM N/A
- Revenue
- BLIN $15,375,000.00
- APM N/A
- Revenue This Year
- BLIN $2.45
- APM N/A
- Revenue Next Year
- BLIN $16.36
- APM N/A
- P/E Ratio
- BLIN N/A
- APM N/A
- Revenue Growth
- BLIN 0.54
- APM N/A
- 52 Week Low
- BLIN $1.05
- APM $0.46
- 52 Week High
- BLIN $2.80
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- BLIN 54.45
- APM 41.41
- Support Level
- BLIN $1.35
- APM $1.41
- Resistance Level
- BLIN $1.59
- APM $2.59
- Average True Range (ATR)
- BLIN 0.08
- APM 0.29
- MACD
- BLIN 0.01
- APM -0.06
- Stochastic Oscillator
- BLIN 49.19
- APM 14.41
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.